KP
KPRX.US Kiora Pharmaceuticals Inc
- Market cap
- USD 5.44M
- P/E
- -
- P/B
- 0.32x
- ROE
- -54.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KPRX.US undervalued?
Graham numberThe Graham number of Kiora Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kiora Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Kiora Pharmaceuticals Inc yet.
Kiora Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kiora Pharmaceuticals Inc
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of …
Full company profileKiora Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kiora Pharmaceuticals Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 669K | 408K | 1.65M | 2.69M | 12.1K | 12.1K | 0.00 | 0.00 | 16.0M | 0.00 | 1.33M |
| Gross Profit | -7.75M | -9.92M | -6.40M | 2.68M | -3.26M | -227K | -134K | -4.03M | 16.0M | -24.8K | - |
| Operating Income | -13.3M | -14.6M | -10.8M | -7.00M | -6.87M | -14.2M | -12.3M | -12.6M | 4.51M | -9.46M | -8.54M |
| EBITDA | -13.3M | -14.5M | -10.7M | -6.79M | -7.47M | -13.9M | -13.6M | -12.4M | 5.70M | -12.1M | -8.02M |
| Net Income | -13.3M | -13.2M | -10.8M | -7.10M | -6.86M | -13.8M | -13.6M | -12.5M | 3.59M | -10.8M | -8.33M |
| EPS | -906 | -556 | -183 | -89 | -60 | -57 | -19 | -23 | 0.87 | -2.64 | -1.32 |
| Balance Sheet | |||||||||||
| Total Assets | 9.73M | 14.3M | 14.3M | 10.1M | 15.3M | 20.1M | 18.7M | 13.7M | 36.5M | 24.3M | 22.4M |
| Total Liabilities | 10.1M | 16.2M | 5.34M | 3.49M | 5.57M | 5.55M | 7.27M | 7.60M | 10.7M | 8.13M | 7.08M |
| Shareholders' Equity | -329K | -1.93M | 8.94M | 6.62M | 9.73M | 14.6M | 11.4M | 6.11M | 25.8M | 16.1M | 15.3M |
| Cash & Short-term Investments | 3.64M | 7.81M | 8.00M | 3.78M | 1.19M | 7.85M | 5.96M | 2.45M | 26.8M | 17.1M | 16.3M |
| Total Debt | 28.7K | 16.1K | 4.72K | 83.9K | 574K | 209K | 106K | 107K | 57.2K | 368K | 287K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.41M | -6.47M | -10.8M | -8.15M | -7.32M | -10.7M | -10.4M | -9.56M | 8.56M | -9.96M | -7.48M |
| Capital Expenditure | 11.0K | 37.0K | 270K | 20.1K | 20.1K | 63.9K | 0.00 | 1.00 | 6.26K | 111K | 38.4K |
| Free Cash Flow | -8.42M | -6.51M | -11.1M | -8.15M | -7.34M | -10.7M | -10.4M | -9.56M | 8.55M | -10.1M | -7.52M |
| Ratios | |||||||||||
| ROE | - | - | -121.0% | -107.2% | -70.5% | -94.5% | -119.1% | -204.8% | 14.0% | -67.2% | -54.4% |
| ROA | -137.1% | -92.4% | -75.7% | -70.2% | -44.8% | -68.4% | -72.7% | -91.3% | 9.9% | -44.7% | -37.2% |
| Net Profit Margin | -1,993.8% | -3,243.5% | -654.2% | -264.2% | -56,901.7% | -114,194.3% | - | - | 22.5% | - | -624.7% |
| Debt to Equity | - | - | 0.00x | 0.01x | 0.06x | 0.01x | 0.01x | 0.02x | 0.00x | 0.02x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kiora Pharmaceuticals Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 7.33K | 0.09 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:9 on Jun 11, 2024.
Who owns Kiora Pharmaceuticals Inc
- Insiders 8.91%
- Institutions 36.82%
- Public & others 54.27%
- Shares outstanding 4.42M
- Free float 3.85M
Top funds holding KPRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 40.3K | 0.91% | +93.58% | Sep 2026 |
| DFA U.S. Vector Equity I | 3.92K | 0.09% | 0.00% | Sep 2026 |
| Dimensional US Core Equity 2 ETF | 3.51K | 0.08% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 3.45K | 0.08% | 0.00% | Sep 2026 |
| DFA US Vector Equity Class F | 2.69K | 0.06% | 0.00% | Aug 2026 |
| Bridgeway Omni Small-Cap Value N | 2.00K | 0.05% | 0.00% | Jun 2026 |
| DFA US Sustainability Core 1 | 1.90K | 0.04% | 0.00% | Sep 2026 |
| DFA U.S. Core Equity 1 I | 1.57K | 0.04% | 0.00% | Sep 2026 |
| Dimensional US Core Equity 1 ETF | 1.57K | 0.04% | 0.00% | Sep 2026 |
| DFA US Social Core Equity 2 Portfolio | 1.24K | 0.03% | 0.00% | Sep 2026 |
| Dimensional US Sustainability Core 1 ETF | 1.23K | 0.03% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 747.00 | 0.02% | 0.00% | Sep 2026 |
Top institutions holding KPRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Perceptive Advisors LLC | 438K | 9.91% | 0.00% | Jun 2026 |
| ADAR1 Capital Management LLC | 168K | 3.80% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 116K | 2.62% | +134.21% | Jun 2026 |
| Two Sigma Investments LLC | 88.8K | 2.01% | 0.00% | Jun 2026 |
| Millennium Management LLC | 74.2K | 1.68% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 58.6K | 1.32% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 37.2K | 0.84% | +24.73% | Sep 2026 |
| Geode Capital Management, LLC | 26.7K | 0.60% | -44.17% | Jun 2026 |
| Vanguard Capital Management, LLC | 19.9K | 0.45% | 0.00% | Jun 2026 |
| Scientech Research LLC | 18.7K | 0.42% | 0.00% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 16.1K | 0.36% | +32.27% | Sep 2026 |
| Vanguard Fiduciary Trust Co | 13.0K | 0.29% | 0.00% | Jun 2026 |
| LPL Financial Corp | 12.5K | 0.28% | 0.00% | Jun 2026 |
| Northern Trust Corp | 11.8K | 0.27% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 10.6K | 0.24% | 0.00% | Jun 2026 |
| UBS Group AG | 1.96K | 0.04% | +50.73% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 1.81K | 0.04% | +30,116.67% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.41K | 0.03% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 837.00 | 0.02% | -15.88% | Jun 2026 |
| SBI Securities Co Ltd | 256.00 | 0.01% | 0.00% | Jun 2026 |
Kiora Pharmaceuticals Inc company profile
- Company name
- Kiora Pharmaceuticals Inc
- Ticker
- KPRX.US
- Exchange
- USA Stocks
- Listed since
- Jul 31, 2015
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
- Fiscal year end
- December
- Address
- 332 Encinitas Boulevard, Encinitas, CA, United States, 92024
- Phone
- 858 224 9600
- Website
- kiorapharma.com
About Kiora Pharmaceuticals Inc
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Kiora Pharmaceuticals Inc management
4- Dr. Brian M. Strem Ph.D.President, CEO & Director · born 1980
- Ms. Melissa Tosca CPAChief Financial Officer · born 1980
- Dr. Stefan Sperl Ph.D.Executive Vice President of CMC & Operations
- Mr. Keith J. Lane M.B.A.Executive VP and Head of Clinical Development & Regulatory Affairs · born 1981